Primary central nervous system lymphoma treated with rituximab plus temozolomide in a second line schedule

被引：0
|
作者：
M. Santisteban
Y. Nieto
S. De la Cruz
J. Aristu
J. L. Zubieta
O. Fernández Hidalgo
机构：
[1] Clínica Universitaria de Navarra,Departmento de Oncología Médica
[2] Clínica Universitaria de Navarra,Departamento de Radioterapia
[3] Clínica Universitaria de Navarra,Servicio de Radiología
来源：
Clinical and Translational Oncology | 2007年 / 9卷
关键词：
CNS; Lymphoma; HDMTX; Rituximab; Temozolomide;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
We report a case of primary CNS lymphoma treated with high-dose methotrexate in the first line. After disease progression the patient received cranial radiotherapy with concomitant temozolomide, followed by rituximab plus temozolomide, with complete remission of the disease maintained for at least two years and without major toxicity.
引用
收藏
页码：465 / 467
页数：2
相关论文
共 50 条
  • [1] Primary central nervous system lymphoma treated with rituximab plus temozolomide in a second line schedule
    Santisteban, M.
    Nieto, Y.
    De la Cruz, S.
    Aristu, J.
    Zubieta, J. L.
    Fernandez Hidalgo, O.
    CLINICAL & TRANSLATIONAL ONCOLOGY, 2007, 9 (07): : 465 - 467
  • [2] Pemetrexed plus rituximab as second-line treatment for primary central nervous system lymphoma
    Hai-Tao Zhao
    Jing Chen
    Sheng-bin Shi
    Jing Tian
    Rong-Jie Tao
    Medical Oncology, 2015, 32
  • [3] Pemetrexed plus rituximab as second-line treatment for primary central nervous system lymphoma
    Zhao, Hai-Tao
    Chen, Jing
    Shi, Sheng-bin
    Tian, Jing
    Tao, Rong-Jie
    MEDICAL ONCOLOGY, 2015, 32 (01) : 1 - 5
  • [4] Combination Therapy with Rituximab and Temozolomide for Recurrent and Refractory Primary Central Nervous System Lymphoma
    Murakami, Mineko
    Fujimaki, Takamitsu
    Asano, Shuichiro
    Nakaguchi, Hiroshi
    Yamada, Shoko M.
    Hoya, Katsumi
    Yamazaki, Kazuto
    Ishida, Yasuo
    Matsuno, Akira
    YONSEI MEDICAL JOURNAL, 2011, 52 (06) : 1031 - 1034
  • [5] INTRAVENOUS RITUXIMAB COMBINED WITH TEMOZOLOMIDE AS A SECOND-LINE THERAPY FOR CD20-POSITIVE PRIMARY CENTRAL NERVOUS SYSTEM MALIGNANT LYMPHOMA
    Matsuno, Akira
    Murakami, Mineko
    Nakaguchi, Hiroshi
    Sasaki, Mitsuyoshi
    Uno, Takeshi
    Ide, Fuyuaki
    Tanaka, Hideki
    Fujimaki, Takamitsu
    NEURO-ONCOLOGY, 2009, 11 (06) : 970 - 970
  • [6] Second line treatment for primary central nervous system lymphoma
    Reni, M
    Ferreri, AJM
    Villa, E
    BRITISH JOURNAL OF CANCER, 1999, 79 (3-4) : 530 - 534
  • [7] Multicenter phase II study of rituximab and temozolomide in recurrent primary central nervous system lymphoma
    Nayak, Lakshmi
    Abrey, Lauren E.
    Drappatz, Jan
    Gilbert, Mark R.
    Reardon, David A.
    Wen, Patrick Y.
    Prados, Michael
    Deangelis, Lisa M.
    Omuro, Antonio
    LEUKEMIA & LYMPHOMA, 2013, 54 (01) : 58 - 61
  • [8] Second-line treatment for primary central nervous system lymphoma
    M Reni
    A J M Ferreri
    E Villa
    British Journal of Cancer, 1999, 79 : 530 - 534
  • [9] The Role of Rituximab in Primary Central Nervous System Lymphoma
    Jacoline E. C. Bromberg
    Matthijs van der Meulen
    Jeanette K. Doorduijn
    Current Oncology Reports, 2020, 22
  • [10] The Role of Rituximab in Primary Central Nervous System Lymphoma
    Bromberg, Jacoline E. C.
    van der Meulen, Matthijs
    Doorduijn, Jeanette K.
    CURRENT ONCOLOGY REPORTS, 2020, 22 (08)
12345